Skyrizi (risankizumab-rzaa) is a prescription drug used to treat certain autoimmune conditions, including plaque psoriasis and Crohn’s disease. It works by attaching to specific proteins in your ...
AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...
AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...
AbbVie’s Skyrizi has already made a name alongside the likes of Novartis’ Cosentyx and Eli Lilly’s Taltz as a powerful biologic for psoriasis. Now, the AbbVie therapy showed it could help patients ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...
This year, AbbVie has continually been a big spender in the TV ad drug stakes, and it’s showing no signs of slowing down. After launching two new Rinvoq commercials this summer, the Big Pharma is now ...
AbbVie ABBV announced positive top-line data from two phase III studies evaluating its psoriasis drug, Skyrizi (risankizumab) for a new indication — active psoriatic arthritis. Skyrizi is presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback